G11.5 Insurance Policy Changes

ICD-10 G11.5 is officially defined as "Hypomyelination - hypogonadotropic hypogonadism - hypodontia." code G11.5 is referenced in 3 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G11.5 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Aug 12, 2025Medium impact
Follitropins and Menotropins (CPB 1082, reviewed 2026-10-09)
Aetna considers follitropins (Gonal-F, Follistim AQ) and menotropins (Menopur) medically necessary for ovulation induction or assisted reproductive technology when the member has completed three or more previous cycles of clomiphene or letrozole, has a risk factor for poor ovarian response to clomiphene or letrozole, has a contraindication or exclusion to them, or is 37 years of age or older. Follitropins are also considered medically necessary for hypogonadotropic hypogonadism treatment that meets listed testosterone and FSH or LH criteria. Commercial plans may require a trial of a lower-cost preferred drug before a higher-cost drug in the same therapeutic class is approved. Use solely for endometrium preparation for frozen embryo transfer, and menotropins for male infertility, are considered experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Follitropins and Menotropins (CPB 1082, reviewed 2026-04-10)
Aetna considers follitropins (Follistim AQ, Gonal-F, Gonal-F RFF) and menotropins (Menopur) medically necessary for commercial medical plans when the criteria in the bulletin are met. For follicle stimulation in assisted reproductive technology or ovulation induction, the member must have completed three or more cycles of clomiphene or letrozole, have a risk factor for poor ovarian response, have a contraindication or exclusion to clomiphene or letrozole, or be 37 years of age or older. Treatment of hypogonadotropic hypogonadism with follitropins for induction of spermatogenesis requires at least two confirmed low pretreatment serum total testosterone levels taken in the morning on separate days plus low or low-normal FSH or LH, and all other indications are considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Chromosomal microarray (CMA) testing may be considered medically necessary as first-line testing in the initial evaluation of individuals with apparent nonsyndromic developmental delay or intellectual disability, autism spectrum disorder, or multiple congenital anomalies not specific to a well-delineated genetic syndrome. CMA is considered investigational for all other conditions of delayed development, including idiopathic growth or language delay. Panel testing using next-generation sequencing is considered investigational in all cases of suspected genetic abnormality in children with developmental delay or intellectual disability, autism spectrum disorder, or congenital anomalies, and CMA testing is not intended for use in the prenatal period.

Watch G11.5

Get one email when a payer policy names G11.5, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G11.5?

There are 3 tracked policy changes affecting code G11.5, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G11.5?

Payers that have issued tracked updates for code G11.5 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code G11.5 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G11.5. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G11.5?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Follitropins and Menotropins (CPB 1082, reviewed 2026-10-09)

Follitropins and Menotropins (CPB 1082, reviewed 2026-04-10)

Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies

What insurance policy changes affect code G11.5?

Which payers have updated policy for code G11.5?

How do I get notified when code G11.5 policy changes?

Why do payers change policies for code G11.5?